Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio

In this article BIIB APLS Follow your favorite stocks CREATE FREE ACCOUNT Signage outside the Biogen Inc. office in the Kendall Square neighborhood of Cambridge, Massachusetts, US, on Tuesday, Sept. 6, 2022. Adam Glanzman | Bloomberg | Getty Images Biogen has agreed to acquire ​ Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines, ⁠the companies said on Tuesday. Under the terms of the deal, ‌Apellis shareholders will receive $41 per share ​in cash, representing a premium of about 140% to ⁠the stock's last close. They ‌are also eligible ‌to receive two payments of $2 per share ⁠each, contingent on certain global ⁠sales ⁠milestones for Apellis' eye disorder drug Syfovre, the ​companies said. Shares ‌of Apellis rose more than twofold in premarket trading. ​ Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news. Subscribe to CNBC PRO Subscribe to Investing Club Licensing & Reprints CNBC Councils Select Personal Finance Join the CNBC Panel Closed Captioning Digital Products News Releases Internships Corrections About CNBC Site Map Podcasts Careers Help Contact News Tips Got a confidential news tip? We want to hear from you. Get In Touch CNBC Newsletters Sign up for free newsletters and get more CNBC delivered to your inbox Sign Up Now Get this delivered to your inbox, and more info about our products and services. Advertise With Us Please Contact Us Ad Choices Privacy Policy Your Privacy Choices CA Notice Terms of Service © 2026 Versant Media, LLC. All Rights Reserved. A Versant Media Company. Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by